| Literature DB >> 12483369 |
J-T Lin1, W-S Wang, C-C Yen, T-J Chiou, J-H Liu, L-T Hsiao, M-H Yang, T-C Chao, C-J Tai, P-M Chen.
Abstract
Autoimmune hemolytic anemia (AIHA) rarely occurs in myelodysplastic syndrome (MDS). A 36-year-old Asian female was diagnosed with MDS (refractory cytopenia with multilineage dysplasia, RCMD) and complicated by AIHA 7 months later. Secondary myelofibrosis developed at the same time. Steroid therapy was ineffective and cyclosporin A (CsA) was discontinued due to its neurotoxicity with the development of leukoencephalopathy. However, the patient achieved a good hematological response after the use of mycophenolate mofetil (MMF, CellCept) with a dose of 1 g/day and prednisolone (15 mg/day). Prednisolone was tapered off over the next 3 weeks. The patient did not require any blood support 4 weeks after the use of MMF and has been hematologically stable for 4 months. To our knowledge, this is the first report of using MMF in treating MDS complicated by AIHA. MMF might be considered as a salvage therapy for patients with refractory anemia complicated by AIHA.Entities:
Mesh：
Substances：
Year: 2002 PMID： 12483369 DOI： 10.1007/s00277-002-0539-3
Source DB: PubMed Journal: Ann Hematol ISSN： 0939-5555 Impact factor: 3.673